NovoCure (NVCR) Free Cash Flow (QoQ) (2015 - 2026)
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) |
|---|---|---|---|---|
| 1 | Abbott Laboratories | 152.82 Bn | 146.17 Bn | 6.27 Bn |
| 2 | Stryker | 115.07 Bn | 112.19 Bn | 3.81 Bn |
| 3 | Medtronic | 95.25 Bn | 87.08 Bn | 5.76 Bn |
| 4 | Boston Scientific | 71.38 Bn | 70.17 Bn | 3.61 Bn |
| 5 | Edwards Lifesciences | 51.08 Bn | 47.41 Bn | 1.29 Bn |
| 6 | Koninklijke Philips | 29.38 Bn | 26.07 Bn | 2.07 Bn |
| 7 | Dexcom | 28.84 Bn | 27.72 Bn | 750.30 Mn |
| 8 | GE HealthCare Technologies | 28.56 Bn | 26.49 Bn | 1.98 Bn |
| 9 | Steris | 20.71 Bn | 20.30 Bn | 697.10 Mn |
| 10 | NovoCure | 1.90 Bn | 1.47 Bn | 135.13 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | 18.48% |
| Dec 31, 2025 | -253.50% |
| Sep 30, 2025 | 169.64% |
| Jun 30, 2025 | 53.71% |
| Mar 31, 2025 | -273.40% |
| Dec 31, 2024 | -3,936.81% |
| Sep 30, 2024 | 97.67% |
| Jun 30, 2024 | 69.63% |
| Mar 31, 2024 | -102.81% |
| Dec 31, 2023 | 19.53% |
| Sep 30, 2023 | 10.45% |
| Jun 30, 2023 | -30.04% |
| Mar 31, 2023 | -125.04% |
| Dec 31, 2022 | -160.64% |
| Sep 30, 2022 | 43.73% |
| Jun 30, 2022 | 232.47% |
| Mar 31, 2022 | -6,853.85% |
| Dec 31, 2021 | -99.38% |
| Sep 30, 2021 | -10.41% |
| Jun 30, 2021 | 70.69% |
| Mar 31, 2021 | -71.08% |
| Dec 31, 2020 | 69.30% |
| Sep 30, 2020 | 199.03% |
| Jun 30, 2020 | 916.10% |
| Mar 31, 2020 | -129.56% |
| Dec 31, 2019 | -67.97% |
| Sep 30, 2019 | 82.92% |
| Jun 30, 2019 | 200.44% |
| Mar 31, 2019 | -144.20% |
| Dec 31, 2018 | 250.55% |
| Sep 30, 2018 | 151.34% |
| Jun 30, 2018 | 52.47% |
| Mar 31, 2018 | -111.25% |
| Dec 31, 2017 | -515.03% |
| Sep 30, 2017 | 132.04% |
| Jun 30, 2017 | 77.63% |
| Mar 31, 2017 | -94.79% |
| Dec 31, 2016 | 59.27% |
| Sep 30, 2016 | -10.96% |
| Jun 30, 2016 | 0.77% |
| Mar 31, 2016 | -17.68% |
| Dec 31, 2015 | -16.62% |
| Sep 30, 2015 | 6.79% |
| Jun 30, 2015 | 14.02% |
| Mar 31, 2015 | -61.33% |